These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7614957)

  • 21. [Azithromycin and bronchopulmonary infections].
    Leophonte P
    Pathol Biol (Paris); 1995 Jun; 43(6):534-41. PubMed ID: 8539078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J
    Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
    Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous azithromycin.
    Garey KW; Amsden GW
    Ann Pharmacother; 1999 Feb; 33(2):218-28. PubMed ID: 10084418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis.
    Howard KB; Blumenschein K; Rapp RP
    Am J Health Syst Pharm; 1999 Aug; 56(15):1521-4. PubMed ID: 10478989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study.
    Kuzman I; Daković-Rode O; Oremus M; Banaszak AM
    J Chemother; 2005 Dec; 17(6):636-42. PubMed ID: 16433194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus.
    So W; Crandon JL; Nicolau DP
    Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
    O'Doherty B; Muller O
    Eur J Clin Microbiol Infect Dis; 1998 Dec; 17(12):828-33. PubMed ID: 10052544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
    Xu S; Xiong S; Xu Y; Liu J; Liu H; Zhao J; Xiong W
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):421-4. PubMed ID: 17120738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.
    van Rensburg D; Fogarty C; De Salvo MC; Rangaraju M; Nusrat R
    J Infect; 2005 Oct; 51(3):201-5. PubMed ID: 16230216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association].
    Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H
    Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863
    [No Abstract]   [Full Text] [Related]  

  • 40. Azithromycin and lower respiratory tract infections.
    Blasi F; Cazzola M; Tarsia P; Cosentini R; Aliberti S; Santus P; Allegra L
    Expert Opin Pharmacother; 2005 Oct; 6(13):2335-51. PubMed ID: 16218893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.